Neuraxis (NRXS) EPS (Basic) (2022 - 2025)

Neuraxis (NRXS) posted EPS (Basic) of -$0.21 for Q4 2025, up 10.83% sequentially from -$0.24 in Q3 2025, and up 10.18% YoY from -$0.19 in Q4 2024.

Neuraxis (NRXS) EPS (Basic) (2022 - 2025) Analysis & Trends

Neuraxis has reported EPS (Basic) for 4 years, with the latest figure at -$0.21 in Q4 2025.

Quarterly EPS (Basic) rose 10.18% year-over-year to -$0.21 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$0.56 (up 52.7% YoY) and the FY2025 annual result came in at -$0.95, up 22.37% from the prior year.
EPS (Basic) advanced to -$0.21 in Q4 2025 per NRXS's latest filing, from -$0.24 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.1 in Q4 2022 and troughed at -$1.63 in Q4 2023.
A 4-year average of -$0.6 and a median of -$0.33 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2024: EPS (Basic) plunged 1485.49% in 2023, then soared 85.72% in 2024.
Over 4 years, EPS (Basic) stood at -$0.1 in 2022, then slumped by 1485.49% to -$1.63 in 2023, then jumped by 85.72% to -$0.23 in 2024, then increased by 10.18% to -$0.21 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.21, -$0.24, and -$0.22 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Neuraxis	75.51 Mn	67.18 Mn	-	-

Download Data